Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.81 |
| ▸ | TP53 | P04637 | 10/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.81 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.81 |
| ▸ | NPC1 | O15118 | 4/20 | 0.80 |
| ▸ | RAB9A | P51151 | 4/20 | 0.80 |
| ▸ | CASP3 | P42574 | 1/20 | 0.80 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.80 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.80 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.80 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.80 |
| ▸ | POLB | P06746 | 9/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | EEF2K | O00418 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22542446 | 0.99 | MAPT (0.82) | MAPTTP53SMN1; SMN2RXFP1NPC1 | |
| SCHEMBL431980 | 0.97 | MAPT (0.79) | MAPTTP53SMN1; SMN2RXFP1NPC1 | |
| SCHEMBL18537666 | 0.90 | MAPT (0.80) | MAPTTP53SMN1; SMN2RXFP1NPC1 | |
| SCHEMBL14955048 | 0.90 | MAPT (0.75) | MAPTTP53SMN1; SMN2RXFP1NPC1 | |
| SCHEMBL426251 | 0.89 | MAPT (0.78) | MAPTTP53SMN1; SMN2RXFP1NPC1 | |
| SCHEMBL10134578 | 0.89 | MAPT (0.81) | MAPTTP53SMN1; SMN2RXFP1NPC1 | |
| SCHEMBL13186366 | 0.89 | MAPT (0.81) | MAPTTP53SMN1; SMN2RXFP1NPC1 | |
| SCHEMBL430370 | 0.89 | MAPT (0.79) | MAPTTP53SMN1; SMN2RXFP1NPC1 | |
| SCHEMBL430702 | 0.89 | MAPT (0.74) | MAPTTP53SMN1; SMN2RXFP1NPC1 | |
| SCHEMBL426553 | 0.88 | MAPT (0.80) | MAPTTP53SMN1; SMN2RXFP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338429-A1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS | UNIVERSITE DE MONTREAL (CA) | 2023-10-26 | — | — | US | disclosed |
| US-20230338429-A1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS | UNIVERSITE DE MONTREAL (CA) | 2023-10-26 | — | — | US | disclosed |
| US-11696928-B2 | Compounds and use thereof in the expansion of stem cells and/or progenitor cells | UNIVERSITE DE MONTREAL (CA) | 2023-07-11 | — | — | US | disclosed |
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2400845-B1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECH INC (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2400845-B1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECH INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| WO-2010099166-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100099672-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099672-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-7645881-B2 | Such as tert-Butyl 3-amino-5-ethyl-4,6-dimethylthieno[2,3-B]pyridine-2-carboxylate which inhibits replication | PTC THERAPEUTICS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | MAPT 138/4885TP53 3355/4885SMN1; SMN2 993/4885 |
| US-20100099672-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | MAPT 4291/4885TP53 2941/4885SMN1; SMN2 4442/4885 |
| US-11696928-B2 | Compounds and use thereof in the expansion of stem cells and/or progenitor cells | MCL1, CD47, BMI1 | MAPT 2684/4885TP53 128/4885SMN1; SMN2 391/4885 |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | MAPT 85/4885TP53 3393/4885SMN1; SMN2 1076/4885 |
| US-20230338429-A1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS | MCL1, CD47, BMI1 | MAPT 2684/4885TP53 128/4885SMN1; SMN2 391/4885 |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | MAPT 85/4885TP53 3393/4885SMN1; SMN2 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.